echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > More protection against variants such as Omicron, Moderna releases clinical data of the first bivalent mRNA new crown vaccine (Phase 2/3)

    More protection against variants such as Omicron, Moderna releases clinical data of the first bivalent mRNA new crown vaccine (Phase 2/3)

    • Last Update: 2022-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently (April 19, 2022), Moderna published the latest phase II/III clinical data of its bivalent mRNA new crown vaccine mRNA-1273.
    211 on Research Square

    .

    Tests have shown that this bivalent mRNA new crown vaccine can be used as a booster to more effectively target new coronavirus variants (beta, delta, omicron)
    .

    mRNA-1273.
    211 is a mixed vaccine of mRNA-1273 and mRNA-1273.
    351 (1:1) launched by Moderna

    .

    mRNA-1273 is an mRNA new crown vaccine against the original virus strain SARS-CoV-2, and mRNA-1273.
    351 is an mRNA new crown vaccine developed against its variant beta

    .

    The Phase II/III clinical trial announced today focused on evaluating the safety and immunogenicity of mRNA-1273.
    211 as a booster in two dose groups [50-µg (n=300) and 100-µg (n=595)]

    .

    Results of clinical assays showed higher neutralizing antibody titers were produced one month and six months after vaccination with mRNA-1273.
    211 compared to mRNA-1273, the currently used mRNA new crown vaccine against the original virus strain SARS-CoV-2

    .

    One month after the subjects received the 50µg mRNA-1273.
    211 booster, neutralizing antibody titers against the omicron variant were 2.
    2 times higher than the 50µg mRNA-1273 booster

    .

    Six months after inoculation, 50µg mRNA-1273.
    211 was still more resistant (2.
    15-fold) to the omicron variant than the 50µg mRNA-1273 booster

    .

    Additionally, this bivalent vaccine induced higher neutralizing antibody responses against variants not explicitly included in the vaccine
    .

    The 50µg/100µg mRNA-1273.
    211 booster induced higher neutralizing antibody responses against SARS-CoV-2 and delta compared to the mRNA-1273 booster

    .

    In terms of safety, the incidence of adverse reactions of mRNA-1273.
    211 was comparable to that of mRNA-1273 (50-µg)

    .

    There were no adverse events of death and SAEs associated with mRNA-1273.
    211 or adverse events leading to clinical discontinuation of mRNA-1273.
    211

    .

    Common local adverse reactions within 7 days of mRNA-1273.
    211 (50-µg) vaccination were pain (85%), and common systemic adverse reactions were fatigue (64%), headache (51%), and myalgia (49%)

    .

    The 100-µg mRNA-1273.
    21 had a higher incidence of adverse reactions compared to the 50-µg mRNA-1273.
    211

    .

    The common local adverse reactions in the 100-µg dose group mRNA-1273.
    21 at 7 days were pain (91%), and the common systemic adverse reactions were fatigue (70%), headache (56%), and myalgia (56%)

    .

    In addition to mRNA-1273.
    211, Moderna currently has a bivalent mRNA new crown vaccine candidate called mRNA-1273.
    214 that is currently in clinical advancement.
    mRNA-1273.
    214 consists of mRNA-1273 (Spikevax) and mRNA new crown vaccine mRNA for Omicron variants -1273.
    529 composition

    .

    Moderna is scheduled to launch as a booster shot this fall
    .

    mRNA-1273.
    214 is currently being evaluated in Phase 2/3 clinical trials, and the first subject vaccination has been completed in early March this year, and preliminary clinical data will be announced in the second quarter of this year

    .

    The editor concluded that SARS-CoV-2 variant strains have caused many new crown epidemics around the world
    .

    The mRNA vaccine against the original new coronavirus has limited resistance to several currently circulating variant strains
    .

    The duration of protective efficacy of the vaccine may be shortened more quickly, and the neutralization titer against the variant virus (6-8 months) drops rapidly
    .

    The launch of the bivalent mRNA vaccine booster may become a powerful tool for dealing with new mutants
    .

    Reference https://doi.
    org/10.
    21203/rs.
    3.
    rs-1555201/v1http:// article/moderna-s-new-bivalent-booster-proves-more-effective-vs-covid-19/https:// covid-19-booster-platform/?keywords=Modernahttps://endpts.
    com/covid-19-roundup-moderna-showcases-progress-on-its-bivalent-booster-novavax-wins-approval-in-japan/
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.